In pancreatic cancer, detection of KRAS and TP53 mutations in exoDNA has been shown to distinguish cancer patients and healthy controls [25], an added advantage to the fact that new therapies targeting p53 mutations are being described [26]. This evidence concerns the gene TP53 and cancer.